Hengsai Biological Dendritic Cell Vaccine Drug Production and Research Project Groundbreaking Ceremony Successfully Held

Lv Jun, Deputy Secretary of the Party Committee and General Manager of Lingang Fengxian CompanyHe delivered a warm speech, firstly, he expressed his warm congratulations on the smooth commencement of the project and expressed his heartfelt thanks to friends from all walks of life who have long supported and cared about the construction of the park. Mr. Lv pointed out that in recent years, with the rapid development of medical science and technology, the tumor treatment is gradually changing from traditional radiotherapy to the precision treatment with immune targeting as the core. As an important member of the body's immune system, the research and development of vaccine drugs for dendritic cells (DC) is regarded as an emerging pathway for anti-tumor treatment, with a broad application prospect. Since signing the contract to move into the park in early 2021, Hengsai Biological has not only successfully completed the pilot R&D project of Phase I DC vaccine, but also ushered in the commencement of the Phase II large-scale production project, which is undoubtedly another major breakthrough made by the company in the field of immunotherapy. Mr. Lv emphasized that the growth of Hengsai Biologicals in the park could not be separated from the hard work of every employee of Hengsai team and the support and help of our partners. In the future, Lingang Fengxian will continue to strengthen its service empowerment and work hand in hand with Hengsai Biologicals to jointly promote the subversive innovation of targeted drugs and bring more effective and safer treatment solutions for tumor patients.